Off-topic for aiqbench
This story was gathered from a source we follow but falls outside AI and quantum coverage, so there is no aiqbench take for it.
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial
Nature1 min read
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial Nature
Read the full article at NatureRelated coverage
AI Products
Presentation: Building Evals for AI Adoption: from Principles to Practice
InfoQ · May 29, 2026
AI Products
[AINews] Reality Checks on AI News (Yegge shuts down Gas Town, Databricks’ +60% Astra cost)
Latent Space · Sep 17, 2026
AI Safety
[AINews] not much happened today
Latent Space · Sep 10, 2026
AI Products
[AINews] High Taste Testers Ep. 1
Latent Space · Oct 17, 2026